• A new retrospective subanalysis of the RE-LY trial suggested similar rates of periprocedural bleeding and thromboembolic complications in nonvalvular atrial fibrillation patients undergoing a surgical or invasive procedure treated with Pradaxa (dabigatran etexilate mesylate), from Boehringer Ingelheim GmbH, of Ingelheim, Germany, compared to warfarin.